Evidence map›Paper›PMID 42367876›Full record

ArticlebioRxiv : the preprint server for biology2026

Antagonism of stress granules key for SARS-CoV-2 infection and pathogenesis.

R Elias Alvarado, Jennifer Chen, Kumari G Lokugamage, Yiyang Zhou, Leah K Estes, Angelica Morgan, Yani Ahearn, Xiangxue Deng, Lilin Lai, Arian Moayyed and 8 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

R Elias AlvaradoDepartment of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, United States.
Jennifer ChenDepartment of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, United States.
Kumari G LokugamageDepartment of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, United States.
Yiyang ZhouDepartment of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, United States.
Leah K EstesDepartment of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, United States.
Angelica MorganDepartment of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, United States.
Yani AhearnDepartment of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, United States.
Xiangxue DengDepartment of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, United States.
Lilin LaiDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Arian MoayyedDepartment of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, United States.
William MeyersDepartment of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, United States.
Jessica A PlanteDepartment of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, United States.
Ken S PlanteDepartment of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, United States.
David H WalkerDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, United States.
Xuping XieDepartment of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, United States.ORCID 0000-0003-0918-016X
Mehul S SutharDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0002-2686-8380
Bryan A JohnsonDepartment of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, United States.
Vineet D MenacheryDepartment of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, United States.

Funding

Virology CoreU19AI171413 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI SARKO, CHRISTOPHER · 2022 to 2023
$75.0M
EMERGING AND TROPICAL INFECTIOUS DISEASEST32AI007526 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI SOONG, LYNN · 1997 to 2025
$3.1M
Identifying host and viral correlates for coronavirus pathogenesisR01AI153602 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI JOHNSON, BRYAN A · 2020 to 2023
$2.0M
The Host Genetics of Age-Dependent SusceptibilityR21AI145400 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI MENACHERY, VINEET D · 2020 to 2021
$451k
Formation of a Novel SARS-CoV-2 Nucleocapsid Dimer: Impacts on Viral and Cellular ProcessesR21AI183054 · NIAID · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI BRUCE, EMILY A. · 2025 to 2025
$439k
NIAID NIH HHS R01 AI153602NIAID NIH HHS R21 AI145400NIAID NIH HHS R21 AI183054NIAID NIH HHS T32 AI007526NIAID NIH HHS U19 AI171413
6 · The paper itself

Abstract

Viruses must subvert host responses to facilitate successful infection. While most antiviral responses are associated with interferons, stress granules (SG) are another barrier to viral infection by inducing translation arrest. To combat SG activity, viruses have evolved mechanisms to disrupt formation and disassemble these complexes. Our prior studies identified residues in SARS-CoV-2 NSP3 (Y138/F145) and nucleocapsid (F17) that independently antagonize SG activity. Disrupting these key residues in NSP3 or nucleocapsid attenuated viral replication, but only modestly impacted

Indexed as

CoronavirusFXR1G3BP1NSP3NucleocapsidSARS-CoV-2Stress Granules

Identifiers

PMID42367876
PMCPMC13308019

What Socratic holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.